BRIEF published on 10/07/2024 at 17:50, 1 year 5 months ago Status of voting rights and capital of Median Technologies as of September 30, 2024 Voting Rights Capital Actions Median Technologies September 30, 2024
BRIEF published on 09/06/2024 at 17:50, 1 year 6 months ago Modification of the rights attached to the categories of shares of Median Technologies Voting Rights Capital Actions Median Technologies Modification Of Rights
PRESS RELEASE published on 09/06/2024 at 17:45, 1 year 6 months ago Changes in the rights attaching to the classes of shares or securities Median Technologies discloses total voting rights and shares as of August 31, 2024, in accordance with regulatory requirements. Company uses AI for cancer diagnoses and treatments globally Voting Rights Shares AI Median Technologies Cancer Diagnosis
BRIEF published on 09/04/2024 at 17:50, 1 year 6 months ago Median Technologies: Promising results for the diagnosis of lung cancer Artificial Intelligence Median Technologies Lung Cancer Eyonis™ LCS Pivotal Study
PRESS RELEASE published on 09/04/2024 at 17:45, 1 year 6 months ago Inside Information / Other news releases Median Technologies to share positive pivotal data for eyonis™ LCS diagnostic software at IASLC 2024 World Conference on Lung Cancer. eyonis™ LCS achieves high accuracy in detecting lung cancer Median Technologies Lung Cancer Eyonis LCS IASLC 2024 Diagnostic Software
BRIEF published on 08/29/2024 at 17:50, 1 year 6 months ago Median Technologies: eyonis achieves REALITY study objectives Screening Median Technologies Lung Cancer Eyonis™ LCS AUC
BRIEF published on 07/18/2024 at 18:01, 1 year 7 months ago Median Technologies unveils half-year results and strategic advances Artificial Intelligence Turnover Backlog ICRO Eyonis™ LCS
PRESS RELEASE published on 07/18/2024 at 17:56, 1 year 7 months ago Inside Information / News release on accounts, results Median Technologies reports record iCRO backlog and eyonis™ LCS on-track for pivotal study readout in August. Revenue at €10.9 million, cash at €16 million. CEO to provide update via webcast on July 24, 2024 Revenue Growth Median Technologies ICRO Eyonis LCS Pivotal Study
BRIEF published on 06/07/2024 at 17:50, 1 year 9 months ago Changes in Shareholder Voting Rights at Median Technologies Share Capital Voting Rights French Regulations Median Technologies Non-voting Shares
PRESS RELEASE published on 06/07/2024 at 17:45, 1 year 9 months ago Changes in the rights attaching to the classes of shares or securities Median Technologies discloses total voting rights and share capital as of May 31, 2024, in compliance with French regulations. The company specializes in AI-driven solutions for cancer diagnosis and treatment Share Capital Voting Rights AI Solutions Median Technologies Cancer Diagnosis
Published on 03/16/2026 at 22:30, 8 hours 49 minutes ago Core Silver Intersects High-Grade Copper-Molybdenum Veins up to 7.31% Cu & 1.01% Mo Confirming Large Porphyry System at Laverdiere
Published on 03/16/2026 at 22:00, 9 hours 19 minutes ago Viemed Healthcare to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19
Published on 03/16/2026 at 21:30, 9 hours 49 minutes ago Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity
Published on 03/16/2026 at 21:00, 10 hours 19 minutes ago Amdocs Brings AI-Accelerated Application Modernization to Enterprises with NVIDIA
Published on 03/17/2026 at 07:05, 13 minutes ago Sequential™ Raises $3.5M to Build AI-Powered Discovery Platform for Multi-Omic Testing and Next-Generation Skin Health Ingredients
Published on 03/17/2026 at 07:03, 16 minutes ago Sartorius Stedim Biotech sharpens strategy with biopharma focus and sets new mid-term growth targets
Published on 03/17/2026 at 07:00, 19 minutes ago PolyPeptide publishes invitation to the annual General Meeting 2026
Published on 03/17/2026 at 07:00, 19 minutes ago Very strong business performance delivered in 2025. Continued growth expected in 2026
Published on 03/17/2026 at 06:59, 19 minutes ago Sartorius sharpens strategy with biopharma focus and sets new mid-term growth targets
Published on 03/17/2026 at 07:00, 19 minutes ago Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 13 hours 19 minutes ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 13 hours 21 minutes ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 13 hours 22 minutes ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026
